No Difference in QoL between NSCLC Patients Receiving Stereotactic Ablative Radiotherapy or Surgery

Share this content:

(ChemotherapyAdvisor) – Patients with non-small cell lung cancer who receive stereotactic ablative radiotherapy maintain the same quality of life as those who receive surgery, according to a team of researchers from The Netherlands. This conclusion is based on a study entitled “Patient-Reported Quality of Life after Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer,” which is published in the July issue of the Journal of Thoracic Oncology.

According to the authors, deterioration in health-related quality of life (HRQOL) is frequently observed after surgery for stage 1 non–small-cell lung cancer. To evaluate changes in patient-reported quality of life, the investigators collected HRQOL data prospectively using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire in 382 consecutive patients treated with SABR. Patients received an SABR dose of 60Gy, which was delivered in 3-, 5-, or 8 treatment fractions, depending on tumor diameter and location. HRQOL data were collected at baseline (pre-SABR), and post-SABR.

The investigators reported a median survival of 40 months; two-year survival: 66%. Local, regional, and distant failure percentages at two years were 6%, 13%, and 22%, respectively. Mean baseline global HRQOL and physical functioning scores were 62.9 ± 1.1 and 61.7 ± 1.1, respectively. Baseline symptom scores were highest for dyspnea (47.1 ± 1.7) and fatigue (37.4 ± 1.3). Except for a non-significant decrease in two to three points per year in physical functioning, no statistically or clinically significant worsening of any of the HRQOL functioning or symptom scores at any follow-up time point was observed.

The investigators concluded: “Patients referred for SABR have substantially worse baseline HRQOL scores than those reported in the surgical literature; clinically relevant deteriorations in HRQOL subscale scores were not observed after SABR.”


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs